Nuvalent Inc
NUVL77.455USD
-0.305-0.39%
Market hours （ET）Quotes delayed by 15 min
5.56BMarket Cap
LossP/E TTM
More Details of Nuvalent Inc Company
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Company Info
Ticker SymbolNUVL
Company nameNuvalent Inc
IPO dateJul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
Number of employees142
Security typeOrdinary Share
Fiscal year-endJul 29
AddressOne Broadway, 14Th Floor
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone18573577000
Websitehttps://www.nuvalent.com/
Ticker SymbolNUVL
IPO dateJul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
Shareholder Types
Shareholders
Proportion
Hedge Fund
48.82%
Investment Advisor
35.80%
Investment Advisor/Hedge Fund
19.30%
Individual Investor
2.87%
Private Equity
2.46%
Research Firm
1.99%
Venture Capital
0.77%
Sovereign Wealth Fund
0.48%
Pension Fund
0.25%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
438
74.96M
112.94%
-1.46M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
2023Q2
230
58.54M
113.63%
-2.82M
2023Q1
202
57.17M
111.42%
-2.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deerfield Management Company, L.P.
17.99M
27.11%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
9.70M
14.61%
+99.92K
+1.04%
Mar 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.94%
-93.95K
-1.75%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
6.68%
-60.03K
-1.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.73M
4.11%
-65.91K
-2.36%
Mar 31, 2025
Commodore Capital LP
1.85M
2.79%
+233.40K
+14.39%
Mar 31, 2025
Shair (Matthew)
1.64M
2.48%
+2.65K
+0.16%
Jun 18, 2025
Perceptive Advisors LLC
1.63M
2.46%
-986.01K
-37.63%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
1.45M
2.18%
--
--
Mar 31, 2025
Wellington Management Company, LLP
1.44M
2.17%
+157.81K
+12.28%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Tema Oncology ETF
3.99%
ALPS Medical Breakthroughs ETF
3.42%
Global X Guru Index ETF
1.27%
SPDR S&P Biotech ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
ProShares Ultra Nasdaq Biotechnology
0.56%
Invesco Nasdaq Biotechnology ETF
0.56%
iShares Health Innovation Active ETF
0.54%
Direxion Daily S&P Biotech Bull 3X Shares
0.53%
iShares Biotechnology ETF
0.35%
View more
Tema Oncology ETF
Proportion3.99%
ALPS Medical Breakthroughs ETF
Proportion3.42%
Global X Guru Index ETF
Proportion1.27%
SPDR S&P Biotech ETF
Proportion0.93%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.88%
ProShares Ultra Nasdaq Biotechnology
Proportion0.56%
Invesco Nasdaq Biotechnology ETF
Proportion0.56%
iShares Health Innovation Active ETF
Proportion0.54%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.53%
iShares Biotechnology ETF
Proportion0.35%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
